HIV dementia and the basal ganglia

Intervirology

Volumn 40, Issue 2-3, 1997, Pages 122-131

  Berger, Joseph R ^a   Nath, Avindra ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; Basal ganglia; Brain; Dopamine; Human immunodeficiency virus; Parkinsonism; Striatum

Indexed keywords

ANTIRETROVIRUS AGENT; ARACHIDONIC ACID; CYTOKINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEF PROTEIN; NITRIC OXIDE; QUINOLINIC ACID; REV PROTEIN; STAVUDINE; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; ZIDOVUDINE;

BASAL GANGLION; BRAIN INFECTION; BRAIN METABOLISM; CLINICAL FEATURE; DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOLOGY; REVIEW;

AIDS DEMENTIA COMPLEX; ANIMALS; BASAL GANGLIA; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS; PARKINSONIA; RNA VIRUSES;

EID: 0031436386     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150539     Document Type: Article

References (141)

1. Snider WD, Simpson DM, Nielsen S, et al: Neurological complications of the acquired immunodeficiency syndrome: Analysis of 50 patients, Ann Neurol 1983;14:403-418.
2. Britton CB, Miller JR: Neurologic complications in acquired immunodeficiency syndrome, Neurol Clin 1984:2:315-339.
3. Janssen RS, Saykin AJ, Cannon L, et al: Neurological and neuropsychological manifestations of HIV-1 infection: Association with AIDS-related complex but not asymptomatic HIV-I infection, Ann Neurol 1989:26:592-600.
4. Berger JR, Moskowitz L, Fischl M, Kelley RE: Neurologic disease as the presenting manifestation of the acquired immunodeficiency syndrome, South Med J 1987:80:683-686.
5. Levy RM, Brcdescn DE, Roscnblum ML: Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience al UCSF and review of the literature, J Neurosurg 1985:62:475-495.
6. McArthur JC: HIV-asssociated CNS syndromes: in Belman A (cd): Course 140: AIDS and the Nervous System, New York, American Academy of Neuroloy, 1993. pp 140-145.
7. Price RW, Brew B, Sidtis J, et al: The brain in AIDS: Central nervous system HIV-I infection and AIDS dementia complex, Science 1988: 239:586-592.
8. Day JJ, Grant I, Atkinson JH, et al: Incidence of AIDS dementia in a two year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort, J Neuropsychiatry 1992;4:15-19.
9. Kleihues P, Leib SL, Strittmattcr C, Wiestler OD, Lang W: IIIV encephalopathy: Incidence, definition and pathogenesis, Acta Pathol Jpn 1991:41:197-205.
10. de la Monte SM, Ho DD, Schooley RT, Hirsch MS, Richardson EP Jr.: Subacute enccphalop-ntyelitis of AIDS and its relation to HTLV-III infection, Neurology 1987:37:562-569.
11. Nielsen SL, Petito CK, Urmachcr CS, Posner JB: Subacute encephalitis in acquired immune deficiency syndrome: A postmortem study, Am J Clin Pathol 1984:82:678-682.
12. Gullotta F, Kuchelmeister K, Masini T, Ghidoni P, Cappricci E: Zur Morphologie der HIV-Enzephalopathien, Zentralbl Allg Pathol Anat 1989:135:5-13.
13. Kato T, Hirano A, Llena JF, Dembitzer HM: Neuropathology of acquired immune deficiency syndrome (AIDS) in 53 autospy cases with particular emphasis on microglial nodules and multinuclcatcd cells, Acta Neuropathol (Berl) 1987:773:287-294.
14. Gray F, Gherardi R, Scaravilli F: The neuropathology of the acquired immune deficiency syndrome (AIDS), Brain 1988:111:245-266.
15. Petito, C: Review of central nervous system pathology in human immunodeficiency virus infection, Ann Neurol 1988:23(suppl):S54-S57.
16. Portegics P, deGans J, Lange JMA, et al: Declining incidence of AIDS dementia complex after introduction of zidovudine treatment, Br Med J 1989:299:819-921.
17. Baccllar H, Munoz A, Miller E, et al: Temporal trends in the incidence of HIV-I related neurologic diseases: Multicentcr AIDS Cohort 1985- 1992. Neurology 1994:44:1892-1900.
18. McArthur JC, Seines OA: HIV-associated dementia, in Berger JR, Levy RM (eds): AIDS and the Nervous System, ed 2. Philadelphia, Lippincott-Ravcn, 1997. pp 527-567.
19. Conant KE, Monaco MG, Major EO: The biology and tropism of human immunodeficiency virus-1 in the nervous system: in Berger JR, Levy RM (eds): AIDS and the Nervous System, cd 2. Philadelphia, Lippincott-Raven,1997. pp 39-57.
20. Epstein LG, Gendelman HE, Lipton SA: Human immunodeficiency virus-1 neuropathogenesis, in Berger JR, Levy RM (eds): AIDS and the Nervous System, ed 2. Philadelphia, Lippincott-Ravcn, 1997. pp 59-76.
21. Masliah E, Ge N, Mucke L: Pathogenesis of HIV-I associated neurodegcneration, Crit Rev Neurobiol 1996:10:57-67.
22. Brew BJ, Sidlis JJ, Roscnblum M, Price RW: AIDS dementia complex, J R Coll Physicians 1988:22:140-143.
23. Kieburtz KD, Epstein LG, Gelbard HA, Grecnamvrc T: Excilotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex: Therapeutic implications, Arch Neurol 1991:48: 1281-1284.
24. Seines OA, MacArthur JC, Gordon B, et al: Patterns of cognitive decline in incident HIV dementia: Longitudinal observations from the multicenter AIDS cohort study (abstract), Neurology 1991:41:252.
25. Navia BA, Jordan BD, Price RW: The AIDS dementia complex, 1. Clinical features, Ann Neurol 1986:19:517-524.
26. Nguyen N, Rimmcr S, Katz B: Slowed saccadcs in the acquired immunodeficiency syndrome, Am J Ophthalmol 1989: 107:356-360.
27. Currie J, Benson E, Ramsdcn B, Perdiccs M, Cooper D: Eye movement abnormalities as a predictor of the acquired immunodeficiency syndrome dementia complex, Arch Neurol 1988:45:949-953.
28. Lekwuwa GU, Branes GR, Cerebral control of eye movements, I, Relationship between cerebral lesion sites and smooth pursuit deficits, Brain 1996:119:473-490.
29. Nath A, Jankovic J, Pettigrew LC: Movement disorders and AIDS, Neurology 1987:37:37-41.
30. Singer C, Berger JR, Bowen BC, Bruce JH, Weiner WJ: Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoenccphaiopathy, Mov Disord 1993:8:113-116.
31. Hollander H, Golden J, Mendclson T, et al: Extrapyramidal symptoms in AIDS patients given low-dose metoclopropaniidc or chlor-promazinc (letter), Lancet 1985:2:1186.
32. Dunlop O, Bjorklund RA, Abdelnoor M, Myrvang B: Five different tests of reaction time evaluated in HIV seropositive men, Acta Neurol Scand 1992:86:260-266.
33. Karlscn NR, Reinvang I, Froland SS: Slowed reaction time in asymptomatic HIV-positive patients, Acta Neurol Scand 1992:86:242-246.
34. Trenkwalder C, Straube A, Paulus W, et al: Postural imbalance: An early sign in HIV-1 infected patients, Eur Arch Psychiatry Clin Neurosci 1992:241:267-272.
35. Amedl G, Hefter H, Elsing C, Strohmeyer G, Freund HJ: Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit, J Neurol 1990:237:362-368.
36. Mintz M, Tardieu Hoyt L, McSherry G, Mcn-delson J, Oleskc J: Levodopa (l,-Dopa) therapy improves motor function in human immunodeficiency virus type-1 (HIV-1) infected children with extrapyramidal syndromes, J Neurovirol 1996:2:44.
37. Belman A: Infants, children and adolescents, in Berger JM, Levy RM (eds): AIDS and the Nervous System, Philadelphia, Lippincott-Raven, 1997. pp 223-254.
38. Edelstein H, Knight RT: Severe parkinsonism in two AIDS patients taking prochlorperazine (letter), Lancet 1987;2:341 -342.
39. Hriso E, Kuhn T, Masdeu J, Grundman M: Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy, Am J Psychiatry 1991; 148:1558-1561.
40. Factor SA, Podskatny GD, Barron KD: Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-patho-logieaI case report, J Neurol Sci 1994:127:114-120.
41. De la Fuente-Aguado J, Bordon J, Moreno JA, Sopena B, Rodriguez A, Martinez-Vazquez C: Parkinsonism in an HIV-infected patient with hypodense cerebral lesion, Tuber Lung Dis 1996;77:191-192.
42. Nath A, Hobson DE, Russell A: Movement disorders with cerebral toxoplasmosis and AIDS, Mov Disord 1993;8:107-112.
43. Aylward EH, Henderer H, McArthur JC, et al: Reduced basal ganglia voumc in HlV-l-asso-caited dementia: Results from quantitative neuroimaging, Neurology 1993:43:2099-2104.
44. Jakobsen J, Gyldensted C, Brun B, Bruhn P, Hclweg-Larsen S, Atrien-Soberg P: Cerebral ventricular enlargement related to neuropsychological measures in unselected AIDS patients, Acta Neurol Scand 1989:79:59-62.
45. Dal Pan GJ, McArthur JH, Aylward E, et al: Patterns of cerebral atrophy in HIV-l-infecied individuals: Results of a quantitative MRI analysis, Neurology 1992:42:2125-2130.
46. Hestad K, McArthur JH, Dal Pan GJ, et al: Regional brain atrophy in HIV-1 infection: Association with specific neuropsychological test performance, Acta Neurol Scand 1993:88:1 12-118.
47. Aylward EH, Brettschneider PD, McArthur JC, et al: Magnetic resonance imaging measurement of gray matter volume reductions in HI V dementia, Am J Psychiatry 1995:52:987-994.
48. Scamiato V, Frank Y, Rozenstein A, et al: Central brain atrophy in childhood AIDS encephalopathy, AIDS 1996:10:1227-1231.
49. Rottcnbcrg DA, Moeller JR, Strother SC, et al: The metabolic pathology of the AIDS dementia complex, Ann Neurol 1987;22:700-706.
50. van Gorp WG, Mandclkern MA, Gee M, et al: Cerebral metabolic dysfunction in AIDS: Findings in a sample with and without AIDS dementia, J Neuropsychiatry Clin Neurosci 1992; 4:280-287.
51. Hinkin CH, van Gorp WG, Mandclkern MA, et al: Cerebral metabolic change in patients with AIDS: Report of a six-month follow-up using positron-emission tomography, J Neuropsychiatry Clin Neurosci 1995;7:180-187.
52. Rottenberg DA, Sidtis JJ, Strother SC, et al: Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia, J Nucl Med 1996:37:1122-1141.
53. LaFrance ND, Pcarlson GD, Schaerf FW: 1-123 IMP-SPECT in HIV-related dementia, Adv Funct Neuroimag 1988:1:9-15.
54. Kramer EL, Sanger JJ: Brain imaging in acquired immunodeficiency syndrome dementia complex, Semin Nucl Med 1990;20:353-363.
55. Meyerhoff DJ, Weiner MW, Fein G: Deep gray matter structures in HIV infection: A proton MR spectroscopic study, AJNR 1996:17:973-978.
56. Lu D, Pavlakis SG, Frank Y, et al: Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS, Radiology 1996;199:423-428.
57. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B: Cerebrospinal lluid dopamine in HIV-1 infection, AIDS 1994:8:67-71.
58. Larsson M, Hagberg L, Foreman A, Norkrans G: Monoamincrgic transmitter systems during HIV infection (abstract MB 2018), Seventh International Conference on AIDS, Florence, 1991.p 186.
59. Britton CB, Cote L, Altsticl L: Cerebrospinal fluid biogenic amine metabolites in patients with AIDS (abstract), Neurology 1989:39 (suppl):380.
60. Sardar AM, Czudek C, Reynolds GP: Dopamine deficits in the brain: The neurochemical basis of parkinsonian symptoms in AIDS, Neuroreport 1996:7:910-912.
61. Navia BA, Jordan BD, Price RW: The AIDS dementia complex, II, Neuropathology, Ann Neurol 1986;19:525-535.
62. Kure K, Weidenhcim DM, Lyman WD, Dickson DW: Morphology and distribution of HIV-I gp4t-positive microglia in subacute AIDS encephalitis: Pattern of involvement resent-blinga multisystem degeneration, Acta Neuro-palhol 1990;80:393-400.
63. Brew BJ, Roscnblum M, Cronin K, Price RW: AIDS dementia complex and HIV-1 brain infection: Clinical-virological correlations, Ann Neurol 1995:38:563-570.
64. Neuen-Jacob E, Arendt G, Wendtland B, Jacob B, Schneeweis M, Wcchslcr W: Frequency and topographical distribution of CD68-positivc macrophages and HIV-1 core proteins in H1V-associatcd brain lesions, Clin Ncuropathol 1993:12:315-324.
65. Reyes MG, Faraldi F, Senseng S, Flowers C, Pariello R: Nigral degeneration in acquired immune deficiency syndrome (AIDS), Acta Neu-ropathol 1991:82:39-44.
66. Carlsson A: Towards a new understanding of dopamine receptors, Clin Neuropharmacol 1995; 18(suppl l):S6-S13.
67. Power C, Kang P-A, Crawford TO, et al: Cerebral white matter changes in AIDS: Alterations in the blood brain barrier, Ann Neurol 1993: 34:339-350.
68. Hartley D, Ilalliday W, Nath A: Adhesion molecules and extracellular matrix components in multiple sclerosis and HIV encephalopathy (abstract 347), First National Conference on Human Retroviruses and Related Infections, Washington, 1993.
69. Berger JR, Andersen AH, Avison MJ: Blood brain barrier breakdown in AIDS dementia: An MR1 study (abstract), J Ncurovirol 1996:2: 31.
70. Harouse JM, Wroblewska Z, Laughlin MA, Hickey WF, Schonwetter BS, Gonzalez-Scara-no F: Human choroid plexus cells can be latently infected with human immunodeficiency virus, Ann Neurol 1989:25:406-411.
71. Falangola MF, Hanly A, Galvao-Castro B, Petito CK: HIV infection of human choroid plexus: A possible mechanism of viral entry' into the CNS, J Neuropathol Exp Neurol 1995:54:497-503.
72. Bagasra O, Lavi E, Bobroski L, Khalili K, Pcs-taner JP, Tawadros R, Pomerantz RJ: Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: Identification by the combination of in situ polymerase chain reaction and immunohistochcmistry, AIDS 1996;10:573-585.
73. Nuovo GJ, Alficric ML: AIDS dementia is associated with massive, activated HIV-1 infection and concomitant expression of several cytokines, Mol Med 1996:2:358-366.
74. Koenig S, Gendelman HE, Orestein JM, et al: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy, Science 1985:233:1089-1093.
75. Saito Y, Sharer LR, Epstein LG, et al: Ovcrex-pression of ncf as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues, Neurology 1994:44: 474-481.
76. Tornalore C, Chandra R, Berger JR, Major EO: HIV-1 infection of subcortieal astrocytes in the pediatric central nervous system, Neurology 1994:44:481-487.
77. Chcng-Maycr C, lannello P, Shaw K, Luciw PA, Levy J: Differential effects of nef on HIV replication: Implications for viral pathogenesis in the host, Science 1989:246:1629-1632.
78. Nath A, Hartloper V, Furer M, Fowkc KR: Infection of human fetal astrocytes with HI V-1: Viral tropism and the role of cell to cell contact in viral transmission, J Neuropathol Exp Neurol 1995:54:320-330.
79. Strizki JM, Albright AV, Sheng H, O'Connor M, Perrin L, Gonzales-Scarano F: Infection of primary human microglia and monocvte-de-rived macrophages with HIV-I isolates: Evidence of differential tropism, J Virol 1996:70: 7654-7662.
80. Tyor WR, Wcssclingh SL, Griffin JW, McArthur JC, Griffin DE: Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy, J AIDS Hum Retrovir 1995:9: 379-388.
81. McArthur JC, Becker PS, Parisi JE, Trapp B, Seines OA, Bomblath DR, Balakrishnan J, Griffin JW, Price D: Neuropathological changes in early HIV-1 dementia, Ann Neurol 1989;26:681-684.
82. Gray F, Lcscs MC, Kcohane C, Parairc F, Marc B, Durigon M, Gherardi R: Early brain changes in HIV infection: Ncuropathological study of 11 HIV seropositive, non-AIDS cases, J Ncuro-pathol Exp Neurol 1992:51:177-185.
83. Tyor WR, Glass JD, Griffin JW: Cytokine expression in the brain during AIDS, Ann Neurol 1992;31:349-360.
84. Wcssclingh SL, Glass J, McArthur JC, Griffin JW, Griffin DE: Cytokine dysrcgulation in HIV-associated neurological disease, Adv Neu-roimmunol 1994;4:199-206.
85. Wesselingh SL, Power C, Glass JD, Tyor WR, McArthur JC, Farber JM, Griffin JW, Griffin DE: Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia, Ann Neurol 1993:33:576- 582.
86. Merrill JE, Benveniste EN: Cytokines in inflammatory brain lesions: Helpful and harmful, Trends Ncurosci 1996:19:331-338.
87. Tomatorc C, Nath A, Amemiya K, Major E: Persistent human immunodeficiency virus type 1 infection in human fetal glia! cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta, J Virol 1991;65:6094-6100.
88. Vcsanan M, Wcssman M, Salminen M, Vaheri A: Activation of integrated human immunodeficiency virus type 1 in human neuroblastoma cells by cytokines tumor necrosis factor alpha and interleukin-6. J Gen Virol 1992:73:1753-1760.
89. Campbell IL, Abrham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Muckel L: Neurologic disease induced in transgenic mice by cerebral ovcrcxpression of interleukin 6. Proc Natl Acad Sci USA 1993;90:10061-10065.
90. Yeung MC, Pulliam L, Lau AS: The HIV-1 envelope protein gp 120 is toxic to human brain cell cultures through the induction of intcrlcu-kin-6 and tumor necrosis factor-alpha, AIDS 1994;9:137-143.
91. Moroni SC, Rossi A: Enhanced survival and differentiation in vitro of different neuronal populations by some cytokines, Intron Dev Ncurosci 1995; 13:41-49.
92. Decker T, Lohmann-Matthcs M, Giffors GE: Cell associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages, J Immunol 1987:5138:957-962.
93. Selmaj KW, Rainc CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro, Ann Neurol 1988;23:339-346.
94. Fine SM, Angel RA, Perry SW, Epstein LG, Gelbard HA: Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes, J Biol Chcm 1996:271:15303-15306.
95. Edfjall C, Jacobsen H, Lolscher H, Mous J: Tumor necrosis factor receptor p55 mediates induction of HIV type I expression in chronically infected UI cells, AIDS Res Hum Retrovir 1996;12:199-204.
96. Fantuzzi L, Gcsani S, Broghi P, et al: Induction of interlcukin-12 by recombinant glycoprotein gp 120 of human immunodeficiency virus type I in human monocytes/macrophages: Requirements of gamma interferon for IL-12 secretion, J Virol 1996:70:4121 - 4124.
97. Brady HJM, Abraham DJ, Pennington DJ, Miles CG, Jenkins S, Dzierzak D: Altered cytokine expression in T lymphocytes from human immunodeficiency virus in Tat transgenic mice, J Virol 1995:69:7622-7629.
98. Philippon V, et al: The basic domain of the lenliviral Tat protein is responsible for damages in mouse brain: involvement of cytokines, Virology 1994:205:519-529.
99. Gibellina D, Zauli G, Carla RM, et al: Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regalaies IL-6 and TFG-P mRNA expression and protein synthesis in peripheral blood monocytes, Br J Haematol 1994:88:261 -267.
100. Rautonen J, Rautonen N, Martin NL, Wara DW: HIV type 1 Tat protein induces immunoglobulin and interleukin 6 synthesis by peripheral blood mononuclear cells, AIDS Res Hum Retrovir 1994:10:781-784.
101. Rasty S, Thatijunta P, Godron J, Khalili K, Smini S, Glorioso JC: Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor pi gene expression, Proc Natl Acad Sci USA 1996:93: 6073-6078.
102. Ge bard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D, ct al: Platelet-activating factor: A candidate human immunodeficiency virus tvpe 1-induced neurotoxin, J Virol 1994:68: 4628-4635.
103. Epstein LG, Gendelman HE: Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms, Ann Neuroi 1993:33:429-436.
104. Genis P, Jett M, Bernton EW, Boyle T, Gcl-bard HA, Dzenko K, Keane RW, Rscnick L, Mizrachi Y, Volsky DJ, et al: Cytokines and arachidonic metabolites produced during human immunodeficiency virus HIVFinfected macrophagc-astroglia interactions: Implications for the neuropathogenesis of HIV disease, J Exp Med 1992;176:1703-1718.
105. 2* in hippocampal neurons, Neuron 1992;9:285-294.
106. Miller B, Sarantis M, Traynclis SF, Attwell D: Potentiation of NMDA receptor currents by arachidonic acid, Nature 1992;355:722-725.
107. Schwartz R, Whetsell WO, Mangano REM: Quinolinic acid: An endogenous metabolite can produce axon sparing lesions in rat brain, Science 1983:219:316-318.
108. Kim JP, Choi DW: Quinolinate neurotoxicity in cortical cell culture, Neurosci !987;25: 423-432.
109. Heyes MP, Brew B, Martin A, Markey SP, Price RW, Bhalla RB, Salazar A: Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome, Adv Exp Med Biol 1991:294:687-690.
110. Heyes MP, Sailo K, Markcv SP: Human macrophages convert /,-tryptophan into the neurotoxin quionolinic acid, Biochcm J 1992: 283:633-635.
111. Dawson VL, Dawson TM, Uhl GR, Snyder SH: Human immunodeficiency virus type 1 coal protein neurotoxicity mediated by nitric oxide in primary cortical cultures, Proc Natl Acad Sci USA 1993:90:3256-3259.
112. Dawson VL, Dawson TM, London ED, Bredl DS, Snyder SH: Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures, Proc Natl Acad Sci USA 1991: 88:6368-6371.
113. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Suchcr NJ, Loscalzo J, Singel DJ, Stamler JS: A redox-based mechanism for the neuro-protcctive and neurodestructivc effects of nitric oxide and related nitroso-compound, Nature 1993:364:626-632.
114. Bukrinsky ML, Nottet HS, Schmidtmayerova H, Dubrovsky L, Flanagan CR, Mullins ME, Lipton SA, Gcndelman HE: Regulation of nitric oxide synthase activity in human immunodeficiency virus type I (HIV-1)-in-fccted monocytes: Implications for HIV-associated neurological disease, J Exp Med 1995: 181:735-745.
115. Giulian D, Jiahan Y, Li X, Tom D, Li J, Wendt E, Lin S-N, Schwartz R, Noonan C, Study of receptor-mediated neurotoxins released by HIV-l-infected mononuclear phagocytes found in human brain, J Neuroscience 1996;16:3139-3153.
116. Giulian D, Vaca K, Noonan CA: Secretion of ncurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990:250:1593- 1596.
117. Werner T, Ferroni S, Saermark T, et al: HIV-I ncf protein exhibits structural and functional similarity to scorpion peptides interacting with K* channels, AIDS 1991;5:1301-1308.
118. Mabrouk K, Rietschoten JV, Vives E, Dar-bon H, Rochat H, Sabatier J-M: Lethal neurotoxicity in mice of basic domains of HIV and SIV Rev proteins, FEBS 1991:289:13-17.
119. Adamson DC, Wilderman B, Sasaki M, Glass JD, McArthur J, C'hristov VI, Dawson TM, Dawson VL: Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996:274:1917-1921.
120. Bennett BA, Rusyniak DE, Hollingsworth CK: gpl20 induced neurotoxicity to midbrain dopamine cultures, Brain Res 1995; 705:168-176.
121. Hill JM, Mervis RF, Avidor R, Moody TW, Brenncman DE: HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates, Brain Res 1993:603:222-233.
122. Levi G, Palrizio M, Bernardo A, Pctrucci TC, Agresti C: HIV coat protein gp120 inhibits the beta adrenergic regulation of astroglial and microglial functions, Proc Natl Acad Sci 1993;90:1541.
123. Mollace V, Colasanti M, Persichini T, Bagctta G, Lauro GM, Nistico G: HIV gpl20 glycoprotein stimulates the inducible isoform of NO synthase in human cultures astrocytoma cells, Biochcm Biophvs Res Commun 1993: 194:439-445.
124. Pulliam L, West D, Haigwood N, Swanson RA: HIV-I envelope gpl20 alters astrocytes in human brain cultures, AIDS Res Hum Retroviruses 1993;9:439-444.
125. Brenncman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB: Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide, Nature 1988:335:639-642.
126. Lipton SA: HIV displays its coat of arms Nature 1994:367:113-114.
127. Sweetnam PM, Saab OH, Wroblcwski JT, Price CH, Karbon EW, Ferkany JW: The envelope glycoprotein of HI V-1 alters NMDA receptor function, Eur J Neurosci 1993;5: 276-283.
128. Lo TK, Fallen CJ, Piser TM, Thayer SA: HIV-1 envelope protein evokes intracellular calcium oscillations in rat hippocampal neurons, Brain Res 1992:594:189-196.
129. Lipton SA: Models of neuronal injury in AIDS: Another role for the NMDA receptor? Trends Neurosci 1992:15:75-79.
130. Nath A, Power C, Geiger JD: Interactions of HIV-I with astrocytes; in Fantini J, Sabatier J-M (eds): Perspectives in Drug Discovery and Design, ESCOM Science Publishers, Amsterdam, 1996. vol 5. pp 30-42.
131. Power C, Johnson RT: HIV-1 associated dementia: Clinical features and pathogenesis, Can J Neurol Sci 1995;22:92-100.
132. Myers G, Korber B, Wain-Hobson S, Smith RF, Pavlakis GN: Human Retroviruses and AIDS, Los Alamos, Los Alamos National Laboratory, 1993.
133. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, Hue B, Baharaoui E: Evidence for ncurotoxic activity of tat from human immunodeficiency virus type I, J Virol 1991:65:961-967.
134. Magnuson DS, Knudsen BE, Geiger JD, Browstone RM, Nath A: Human immunodeficiency virus type 1 tat activates non-N-methvl-D-aspartatc excitatory amino acid receptors and causes neurotoxicity, Ann Neurol 1995;37:373-380.
135. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DK, Haughey N, Geiger JD: Identification of a human immunodeficiency virus type 1 Tat epitope that is ncuroexcitatory and neurotoxic, J Virol 1996:70:1475-1480.
136. Ensoli B, Buonaguro L, Barillari G, Fiorclli V, Gcndelman R, Morgan RA, Wingfield P, Gallo RC: Release, uptake, and effects of extracellular human immunodeficiency virus type I Tat protein on cell growth and viral transactivation, J Virol 1993:67:277-287.
137. Tardicu M, Hery S, Pcudcnicr O, et al: HIV type-1 infected cells can destroy human neural cells after cell to cell adhesion, Ann Neurol 1992:32:11-17.
138. Hayman M, Arbulhnott G, Harkiss G, Brace H, Filippi P, Philippon V, Thomson D, Vigne R, Wright A: Neurotoxicity of peptide analogues of transactivating protein tat from maedi-visna virus and human immunodeficiency virus, Neuroscience 1993:53:1-6.
139. Weeks BS, Lieberman DM, Johnson B, Roque E, Green M, Lowenstein P, Oldfield EH, Klcinman 11K: Neurotoxicity of the human immunodeficiency virus type 1 Tat transactivator to PC 12 cells requires the Tat amino acid 49-58 basic domain, J Neurosci 1995; 42:34-40.
140. New DR, Ma M, Epstein LG, Nath A, Gelbard HA: Human immunodeficiency virus type I Tat protein induces death by apoptosis in primary human neuron cultures, J Ncuro-virol 1997:3:168-173.
141. Olafson K, Del Bigio M, Peeling J, Jones M, Nath A: Human immunodeficiency virus protein, Tat, causes inflammation, apoptosis and atrophy in rat brain, J Neurovirol 1996:2: 18.